Cellectis CLLS
NASDAQ CLLS
$3.24 -0.08 (-2.41%)
At close: Sep 4, 2026 · 4:00 PM EDT

Cellectis (CLLS) Change in Receivables (2015 - 2026)

Cellectis (CLLS) posted quarterly Change in Receivables of $7.9 million for Q1 2026, up 3550.0% year-over-year from $217397.3 in Q1 2025, and up 116.45% quarter-over-quarter from $3.7 million in Q3 2025.

Analysis

Cellectis (CLLS) Change in Receivables (2015 - 2026) Analysis & Trends

Cellectis' Change in Receivables history runs 12 years deep, the most recent figure standing at $7.9 million for Q1 2026.

  • In Q1 2026, Change in Receivables rose 3550.0% year-over-year to $7.9 million; the TTM figure through Mar 2026 stood at $9.5 million (down 85.59% YoY), while the FY2024 annual figure was $52.6 million, up 2235.52% from the prior year.
  • Change in Receivables for Q1 2026 stood at $7.9 million, up from $3.7 million in the prior quarter.
  • The five-year high for Change in Receivables was $61.4 million in Q2 2024, with the low at -$13.5 million in Q1 2024.
  • The 5-year median for Change in Receivables is $171500.0 (2022), against an average of $3.8 million.
  • The sharpest annual moves came in 2023 and 2026: Change in Receivables sank 3769.7% in 2023, then surged 3550.0% in 2026.
  • Cellectis' Change in Receivables stood at $578000.0 in 2022, then surged by 203.29% to $1.8 million in 2023, then jumped by 144.78% to $4.3 million in 2024, then decreased by 14.57% to $3.7 million in 2025, then surged by 116.45% to $7.9 million in 2026.
  • Business Quant data shows CLLS's Change in Receivables at $7.9 million in Q1 2026, $3.7 million in Q3 2025, and -$1.9 million in Q2 2025.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Change in Receivables (Qtr)
1 Vertex Pharmaceuticals 138.47 Bn 130.62 Bn 2.84 Bn 140.20 Mn
2 Regeneron Pharmaceuticals 85.18 Bn 77.19 Bn 3.93 Bn 838.50 Mn
3 Argenx Se 63.38 Bn 58.19 Bn 1.37 Bn -
4 Moderna 58.09 Bn 52.95 Bn 52.00 Mn -53.00 Mn
5 Revolution Medicines 44.33 Bn 44.33 Bn - -
6 BeOne Medicines 40.02 Bn 34.92 Bn 1.53 Bn 117.58 Mn
7 Alnylam Pharmaceuticals 35.57 Bn 32.27 Bn 992.69 Mn 31.60 Mn
8 Royalty Pharma 28.45 Bn 27.61 Bn - -
9 Insmed 27.48 Bn 26.32 Bn 358.27 Mn 37.16 Mn
10 Cellectis 321.90 Mn 155.05 Mn - 263,000.00
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 263,000.00
Mar 31, 2026 7.94 Mn
Dec 31, 2025 -6.57 Mn
Sep 30, 2025 3.67 Mn
Jun 30, 2025 -1.88 Mn
Mar 31, 2025 -230,000.00
Dec 31, 2024 4.29 Mn
Sep 30, 2024 376,000.00
Jun 30, 2024 61.39 Mn
Mar 31, 2024 -13.46 Mn
Dec 31, 2023 1.75 Mn
Sep 30, 2023 -497,000.00
Jun 30, 2023 2.27 Mn
Mar 31, 2023 -1.28 Mn
Dec 31, 2022 578,000.00
Sep 30, 2022 -886,000.00
Jun 30, 2022 -2.85 Mn
Mar 31, 2022 -33,000.00
Dec 31, 2021 -22.86 Mn
Sep 30, 2021 5.45 Mn